FLASH NEWS LIVE

Apellis Pharma Skyrockets on Biogen Deal. Is It Too Late to Chase APLS Stock?

Apellis Pharma Skyrockets on Biogen Deal. Is It Too Late to Chase APLS Stock?

Apellis Pharma stock more than doubled as Biogen announced a $5.6 billion acquisition. But for investors looking to jump into APLS shares now, the ship has already sailed.

Read Full Article →

📱 Tip: Tap the 🔗 Share icon in Safari and choose Add to Home Screen to install World Trade Factory.